GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actelion Ltd (OTCPK:ALIOF) » Definitions » Sloan Ratio %

Actelion (Actelion) Sloan Ratio % : -7.32% (As of Mar. 2017)


View and export this data going back to . Start your Free Trial

What is Actelion Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Actelion's Sloan Ratio for the quarter that ended in Mar. 2017 was -7.32%.

As of Mar. 2017, Actelion has a Sloan Ratio of -7.32%, indicating the company is in the safe zone and there is no funny business with accruals.


Actelion Sloan Ratio % Historical Data

The historical data trend for Actelion's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actelion Sloan Ratio % Chart

Actelion Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Sloan Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.14 17.12 -14.28 -2.81 -7.67

Actelion Quarterly Data
Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.75 -5.11 -2.93 -7.83 -7.32

Competitive Comparison of Actelion's Sloan Ratio %

For the Biotechnology subindustry, Actelion's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Actelion's Sloan Ratio % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actelion's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Actelion's Sloan Ratio % falls into.



Actelion Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Actelion's Sloan Ratio for the fiscal year that ended in Dec. 2016 is calculated as

Sloan Ratio=(Net Income (A: Dec. 2016 )-Cash Flow from Operations (A: Dec. 2016 )
-Cash Flow from Investing (A: Dec. 2016 ))/Total Assets (A: Dec. 2016 )
=(683.133-902.031
--60.507)/2066.389
=-7.67%

Actelion's Sloan Ratio for the quarter that ended in Mar. 2017 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Mar. 2017 )
=(724.343-960.356
--65.346)/2332.191
=-7.32%

Actelion's Net Income for the trailing twelve months (TTM) ended in Mar. 2017 was 188.118 (Jun. 2016 ) + 226.725 (Sep. 2016 ) + 112.838 (Dec. 2016 ) + 196.662 (Mar. 2017 ) = $724 Mil.
Actelion's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2017 was 255.05 (Jun. 2016 ) + 282.604 (Sep. 2016 ) + 220.636 (Dec. 2016 ) + 202.066 (Mar. 2017 ) = $960 Mil.
Actelion's Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2017 was -27.385 (Jun. 2016 ) + -12.33 (Sep. 2016 ) + -16.496 (Dec. 2016 ) + -9.135 (Mar. 2017 ) = $-65 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Actelion  (OTCPK:ALIOF) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Mar. 2017, Actelion has a Sloan Ratio of -7.32%, indicating the company is in the safe zone and there is no funny business with accruals.


Actelion Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Actelion's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Actelion (Actelion) Business Description

Traded in Other Exchanges
N/A
Address
Actelion is a Swiss biopharmaceutical firm with several products on the market, largely focused on pulmonary arterial hypertension: Tracleer, Opsumit, Uptravi, Ventavis, and Veletri treat various stages of the disease via different methods of administration. Zavesca is a second-line option for Gaucher disease, and Valchlor treats a rare form of blood cancer. Actelion has created a global commercial infrastructure for its approved orphan drugs and has supplemented its internal pipeline through in-licensing and acquisitions.

Actelion (Actelion) Headlines

From GuruFocus

Actelion Still On Growth Track

By reports.droy reports.droy 02-18-2015

Eaton Vance Worldwide Health Sciences Fund 4th Quarter Commentary

By Holly LaFon Holly LaFon 02-14-2017

Jean Hynes Reduces Stake in Actelion

By Kyle Ferguson Kyle Ferguson 08-03-2016

Eaton Vance Worldwide Health Sciences Fund 4th Quarter Commentary

By Holly LaFon Holly LaFon 01-24-2017